Abstract

Background

Comprehensive Geriatric Assessment (CGA) is the gold standard to help oncologists select the best cancer treatment for their older patients. Some authors have suggested that the concept of frailty could be a more useful approach in this population. We investigated whether frailty markers are associated with treatment recommendations in an oncogeriatric clinic.

Methods

This prospective study included 70 years and older patients with solid tumors and referred for an oncogeriatric assessment. The CGA included nine domains: autonomy, comorbidities, medication, cognition, nutrition, mood, neurosensory deficits, falls, and social status. Five frailty markers were assessed (nutrition, physical activity, energy, mobility, and strength). Patients were categorized as Frail (three or more frailty markers), pre-frail (one or two frailty markers), or not-frail (no frailty marker). Treatment recommendations were classified into two categories: standard treatment with and without any changes and supportive/palliative care. Multiple logistic regression models were used to analyze factors associated with treatment recommendations.

Results

217 patients, mean age 83 years (± Standard deviation (SD) 5.3), were included. In the univariate analysis, number of frailty markers, grip strength, physical activity, mobility, nutrition, energy, autonomy, depression, Eastern Cooperative Oncology Group Scale of
Performance Status (ECOG-PS), and falls were significantly associated with final treatment recommendations. In the multivariate analysis, the number of frailty markers and basic Activities of Daily Living (ADL) were significantly associated with final treatment recommendations ($p<0.001$ and $p = 0.010$, respectively).

**Conclusion**

Frailty markers are associated with final treatment recommendations in older cancer patients. Longitudinal studies are warranted to better determine their use in a geriatric oncology setting.

---

**Introduction**

Both the incidence of cancer and the risk of death due to cancer increase with age [1]. Demographic projections for 2030 suggest that people older than 65 will represent almost 25% of the European population, and death by cancer will represent the first cause of mortality. The elderly population is heterogeneous in terms of health problems such as comorbidities, disabilities, polypharmacy, cognition, mood, social issues, etc. Management of cancer in the elderly population is challenging because of potential underlying health problems that may interfere with treatment. The International Society of Geriatric Oncology (SIOG) [2], and several literature reviews recommend an approach based on comprehensive geriatric assessments (CGA) to help specialists in selecting the best cancer treatment [1,3,4,5,6].

Balducci’s and colleagues proposed recommendation for treatment plan based on CGA results. Three groups were defined: vulnerable, intermediate and palliative. For the intermediate group, decision could be either palliative or curative. Literature reviews have recently questioned decision making strategies [7,8,9]. In studies that examined the impact of CGA in treatment decision-making [10,11,12,13,14] only three [11,12,14] showed that, in 30% to 50% of patients, CGA led to changes in the oncologic treatment plan. Then additional tools could be, therefore, necessary in the older cancer population.

Using data from the Cardiovascular Health Study, Fried and colleagues [15] identified five frailty markers: nutrition, mobility, strength, energy, and physical activity. They reported that older persons with at least three of the five frailty markers are at a significantly increased risk of suffering from adverse outcomes such as falls, worsening mobility, disability, hospitalization, and death within three years. Moreover, the presence of at least one of these markers confers an higher risk of adverse outcomes [15,16]. In oncology setting, presence of frailty markers predicts treatment toxicity and risk of early death [17]. In oncology surgery setting, frailty markers are associated with an higher risk for postoperative complications [18,19] and length of stay [18]. Thus, the concept of frailty could be a useful approach to detect potential underlying health problems that may interfere with treatment in older cancer patients [20].

The aim of this study was to assess whether frailty markers and CGA are associated with cancer treatment recommendations in an oncogeriatric clinic.

**Materials and Methods**

**Ethics Statement**

Informed consent was not obtained from the patients. The database was anonymous. The Ethics Committee of the Centre gérontologique départemental of Marseille, France, approved the...
study and its protocol. The French data protection agency (Commission Nationale de l’Informatique et des Libertés–CNIL) approved the use of the database for clinic research (record number: 1641373 v.0. January 2, 2013).

Study Setting, Sample, and Design
This cross-sectional descriptive study was carried out for the purpose of oncogeriatric assessment by a single team between January 2008 and June 2013 in three centers of Marseille. The team included two trained geriatricians in oncology, nurse practitioners, dietitians, a social worker, and pharmacists.

Inclusion criteria for this study were: 70 years and older patients, having a solid tumor and referred by their physician to the oncogeriatric clinics after an initial cancer treatment plan. Patient with life expectancy estimated to be 3 month and/or previously treated with chemotherapy or radiotherapy, or patient seen for follow-up, were excluded from the study.

The following procedure was applied (Fig 1). Older cancer patients were referred to oncologist or surgeon for cancer assessment. Initial cancer treatment plan was discussed during a 1st multidisciplinary team meeting (MDT). After MDT, an initial cancer treatment plan was decided (surgery, radiotherapy, chemotherapy, supportive/palliative care) requiring or not CGA. After CGA, oncologist and geriatricians met during a 2nd MDT to decide final treatment recommendations.

Geriatric recommendations might be proposed depending on the geriatric syndrome identified.

Data Collection
Age, sex, and Eastern Cooperative Oncology Group Scale of Performance Status (ECOG-PS) [21] were recorded by nurse practitioner. Oncology data, including type and stage of cancer; treatment cancer plan and reason for assessment were collected by the geriatrician. CGA data and frailty markers were collected by both the geriatrician and the nurse practitioner.
The CGA used both self-report and performance-based measures. The CGA included nine domains: functional status, comorbidities, medication, cognition, nutrition, mood, neurosensory deficits, falls, and social status. The functional status was assessed using activities of daily living (ADL), instrumental activities of daily living (IADL), and the Eastern Cooperative Oncology Group Scale of Performance Status (ECOG-PS). ADL disability was assessed using six tasks of the Katz index [22]. IADL disability was assessed using the seven Older American Resources and Services (OARS) items [23]. The denominator was adjusted to take into account patients who did not normally perform an activity such as cooking or doing laundry. Disability in ADL or IADL was defined as the need for assistance to complete at least one ADL or IADL, respectively. The comorbid conditions were codified according to the International Coding Diseases (ICD-10th revision, French version). Ten groups of comorbidities were selected: cardiovascular disease, hypertension, diabetes, depression, dementia, other neurological diseases, respiratory disease, gastrointestinal disease, osteoarticular disease, and renal failure [24]. In each group, patients scored positive if they had one or more comorbidities. Burden comorbidity was defined by the presence of three or more comorbidities [25]. The number of medications (excluding those for cancer treatment) was calculated for each patient. The cognition was assessed by the following tests: the Mini-Mental State Examination [26] (MMSE), the Mini Cog [27], the Montreal Cognitive Assessment (MoCA) [28], or the Clock test [29]. Cognitive disorders were defined by MMSE or MoCA < 26 and/or a pathologic Cog or Clock test. The 4-item Geriatric Depression Scale (mini GDS) was used to screen for depression. A score of 1 or more indicated depression [30]. Patients with trouble hearing and/or requiring hearing aids, and/or patients with trouble seeing (despite the use of glasses) were considered to have a neurosensory deficit. Patients who had experienced one or more falls in the previous six months were considered to have a positive history of falls. The nutritional status was assessed by body mass index (BMI). A BMI under 22 was considered to be underweight and indicated under-nutrition [31]. As no gold standard to evaluate social support and home care services was available, the following questions were asked: “If necessary, do you have someone who can care for you? If yes, who is it? Do you have professional help at home? If yes, what kind? Do you have family support or home care services?”

All patients were classified into the three Balducci groups [32]: Group I: patients who are functionally independent for ADL and without serious comorbidity, Group II: patients who are independent for ADL and/or have 1 to 2 comorbidities and/or no geriatric syndrome, Group III: age ≥ 85 years, patients who are dependent for at least one ADL and/or have 3 or more comorbidities and/or at least 1 geriatric syndrome.

The five frailty markers adapted from the Fried phenotype were also recorded: nutrition, energy, strength, physical activity, and mobility [15]. The nutritional status was assessed by two self-report questions: “In the last year, have you lost more than ten pounds unintentionally? [15]. In the last three months, has food intake decreased for whatever reason?” [33]. An affirmative answer to one of the two questions indicated a positive marker of frailty for nutrition. The energy was assessed using a visual scale ranging from 0 (no energy) to 10 (full of energy). A score < 3 indicated a positive marker of frailty for energy [16]. The strength was assessed by three measurements of grip strength (in kilograms) in the dominant hand using a Jamar handheld dynamometer. The maximal grip strength was selected for the analysis. The lowest quintile by sex and BMI was considered a positive marker of frailty for strength [15]. The physical activity was assessed by a validated self-report question from the Canadian Study of Health and Aging Risk Factor Questionnaire (RFQ) [34]. No exercise or a low level of exercise was considered to be a positive marker of frailty for physical activity. The mobility was assessed by the Timed Up and Go test (TUG) [35] or the one-leg standing balance test [36]. A TUG time of less than ten seconds or the inability of a patient to balance on one leg for more
than five seconds was considered to be a positive marker of frailty for mobility. Patients who
had three or more markers were classified as frail, patients with one or two markers as pre-frail,
and patients with no markers as not-frail [15]. CGA data and frailty markers were collected by
geriatricians and nurse practitioners except data for nutrition which were collected by the
dietitian.

The final treatment recommendations were classified into two categories: Standard treat-
ment (corresponding to the initial treatment plan, with or without adaptation when surgery,
chemotherapy or radiotherapy were recommended), modified treatment (patient for whom
supportive / palliative care were recommended after geriatric assessment instead of initial treat-
ment plan included surgery, chemotherapy or radiotherapy)

Geriatric recommendations were proposed in eight domains: nutrition, mobility, usual
treatment modifications, cognition, comorbidities, functional status, depression, neurosensory
deficit.

Data Analysis

Descriptive statistics of patient characteristics, and health and functional status measures
were calculated. A univariate comparison of the three groups defined by the treatment
changes/recommendations was performed using the chi-square test or the Fisher exact test
for qualitative variables and the Analysis of variance (ANOVA) or the Kruskal-Wallis non-
parametric test for quantitative ones. To analyze independent factors associated with treat-
ment recommendations, a multivariate regression statistical analysis was performed. We
entered into the model variables which were associated in the univariate analysis with a p-
value <0.20, excluding variables which presented collinearity with other factors. Associations
with a p-value <5% were considered significant. All statistical analysis was carried out using
statistical software SPSS v17.

Results

In all, 217 patients, with a mean age of 83 years (± SD 5.3), were included in this study.
Women represented 58% (Table 1). Digestive cancer was the most common diagnosis, fol-
lowed by urogenital cancer (39% and 21%, respectively). More than one-fourth of the patients
had metastases. Half were referred before chemotherapy and 39% before surgery. Ninety-five
percent of patients lived at home. Fewer than one out of six had more than three comorbidities.
Almost half had more than five drugs. About one-third had ADL disability, and two-thirds had
IADL disability. Roughly 40% had cognitive disorders and depression. One-fourth had fallen
in the last six months. The most prevalent of the frailty markers were mobility (77%), physical
activity (65%), and nutrition (61%). Only 7% of patients were non-frail; 40% were frail.
According to the Balducci classification, only 2% of patients were fit, and 7% were frail.

After assessment, the number of geriatric recommendations was around 2 per patient. The
most prevalent recommendations were nutrition (46%) and mobility (41%). Only 24% of
patients needed of cognition recommendation and 11% needed depression recommendation
(Table 1).

In the univariate analysis, number of frailty markers, physical activity, mobility, nutrition,
grip strength, energy as well as ADL, IADL, depression, ECOG-PS, and falls were significantly
associated with final treatment recommendations (Table 2). Final treatment recommendations
weren’t associated with Balducci’s classification (p = 0.58). In the multivariate analysis, a few of
the frailty markers and ADL were significantly associated with final treatment recommenda-
tions (respectively p < 0.001 and p = 0.010) (Table 2).
Table 1. Characteristics of patients (N = 217).

| Characteristics                                                                 | Mean +/- SD; n, % |
|---------------------------------------------------------------------------------|------------------|
| Age (years)                                                                     | 83.2 ± 5.3       |
| Female                                                                          | 125 (57.6%)      |
| Patients, previously diagnosed, followed at (N = 212)                           |                  |
| Oncology departments                                                            | 141 (65.0%)      |
| Geriatric departments                                                           | 67 (30.9%)       |
| General/ internal medicine                                                      | 4 (1.8%)         |
| Tumor (N = 216)                                                                 |                  |
| Digestive                                                                       | 84 (39.3%)       |
| Urological                                                                      | 46 (21.2%)       |
| Breast and gynecological                                                       | 38 (17.5%)       |
| Lung                                                                            | 25 (11.5%)       |
| Other                                                                           | 23 (10.6%)       |
| Presence of metastasis (N = 212)                                               | 61 (28.8%)       |
| Reason for consultation (N = 214)                                               |                  |
| Evaluation before chemotherapy                                                   | 114 (53.3%)      |
| Evaluation before surgery                                                       | 85 (39.2%)       |
| Other                                                                           | 25 (11.5%)       |
| Geriatric Assessment                                                            | n, %             |
| Living at home (N = 210)                                                        | 201 (95.7%)      |
| Presence of social support (N = 211)                                            | 184 (87.2%)      |
| Comorbidities (N = 214)                                                         |                  |
| 3 or more comorbidities                                                        | 38 (17.8%)       |
| Cardiovascular                                                                  | 110 (51.4%)      |
| Hypertension                                                                    | 106 (49.5%)      |
| Osteoarticular                                                                  | 88 (41.1%)       |
| Diabetes                                                                        | 51 (23.8%)       |
| Respiratory                                                                     | 36 (16.8%)       |
| Depression                                                                      | 25 (11.7%)       |
| Digestive                                                                       | 24 (11.2%)       |
| Neurological                                                                    | 23 (10.7%)       |
| Chronic renal failure                                                           | 18 (8.4%)        |
| Dementia                                                                        | 15 (7.0%)        |
| Previous cancer                                                                 | 54 (25.2%)       |
| Drugs 5 (N = 206)                                                               | 99 (48.1%)       |
| Functional status                                                               |                  |
| Abnormal ADL (N = 204)                                                          | 82 (38.3%)       |
| Abnormal IADL (N = 215)                                                         | 137 (63.7%)      |
| ECOGS PS >1 (N = 92)                                                            | 27 (29.3%)       |
| Cognitive impairment (N = 211)                                                  | 84 (39.8%)       |
| BMI < 22kg/m² (N = 166)                                                         | 39 (23.5%)       |
| History of Falls (N = 217)                                                      | 55 (25.3%)       |
| Depression (N = 213)                                                            | 80 (37.5%)       |
| Neurosensory deficit                                                            |                  |
| Visual deficit (N = 204)                                                        | 80 (39.2%)       |
| Hearing deficit (N = 203)                                                       | 91 (44.8%)       |
| Balducci classification (N = 217)                                               |                  |
| Group I (fit)                                                                   | 5 (2.3%)         |
| Group II (intermediate)                                                         | 197 (90.8%)      |
| Group III (frail)                                                               | 15 (6.9%)        |
| Frailty markers                                                                  | n, %             |
| Mobility (N = 200)                                                              | 155 (77.5%)      |
| Physical activity <3 (N = 197)                                                  | 129 (65.5%)      |
| Nutrition (N = 215)                                                             | 131 (60.9%)      |
| Grip strength (N = 184)                                                         | 49 (26.6%)       |

(Continued)
Discussion

To our knowledge, this is the first study to address the association between frailty markers and treatment recommendations in older cancer patients. Frailty markers were highly prevalent. Almost 90% of patients presented with at least one frailty marker. We found a significant association between the number of frailty markers and ADL, and final treatment recommendations proposed after the 2nd MDT. As the number of frailty markers increased, treatment recommendations were accordingly oriented toward modified treatment. On the other hand, the absence of frailty markers was associated with standard treatment. We observed although only 7% of our patients were considered as frail in Balbucci classification, we proposed for 40% a modified treatment.

Choosing the most sensitive tools to accurately assess health status is a major issue in geriatric oncology. The International Society of Geriatric Oncology (SIOG) and numerous literature reviews propose the use of a Comprehensive Geriatric Assessment (CGA) to determine optimal oncologic care on the basis of the patient’s health status rather than empirical evidence. However, several recent literature reviews have questioned the real value of the CGA in older cancer patients, as CGA seems to have a ceiling effect in detecting vulnerability in this population [7,8,9]. According to literature data, patients referred to oncology represent a population that differs from traditional geriatric patients: they have fewer comorbidities, fewer cognitive disorders, and good functional status at the time of diagnosis [37,38]. As in Chaibi’s and Caillet’s studies [11,14], we found a significant association with final treatment recommendations and ADL. However, our study found that abnormal ADL is observed in fewer than 30% of older cancer patients referred in oncology. A need for more sensitive tools is then indicated to identify patients who appear healthy but are vulnerable to complications in response to aggressive cancer treatments [8]. As patients get older, the risks of treatment toxicities increase. The result
Table 2. Univariate and multivariate logistic regression models showing the association between final treatment recommendations, CGA and Frailty markers.

|                      | Univariate logistic regression | Multivariate logistic regression |
|----------------------|--------------------------------|---------------------------------|
|                      | Standard treatment with or without any changes | Modified treatment | Univariate OR [95%CI] | p | Multivariat OR [95%CI] | p-value |
| Age (years)          | 82.3±5.1                        | 83.8 (±5.4)                  | 0.9 [0.9;1.0]          | 0.08 | -                     | -       |
| Sex                  |                                 |                               |                           |      |                       |         |
| Male                 | 61 (66.3%)                      | 31 (33.7%)                   | 1                        | 0.093 | -                     | -       |
| Female               | 68 (54.4%)                      | 57 (45.6%)                   | 0.6 [0.3;1.1]           |      |                       |         |
| Social support       |                                 |                               |                           |      |                       |         |
| No                   | 17 (63%)                        | 10 (37.0%)                   | 1                        | 0.63 | -                     | -       |
| Yes                  | 107 (58.2%)                     | 77 (41.8%)                   | 0.8 [0.4;1.8]           |      |                       |         |
| Comorbidities ≥ 3   |                                 |                               |                           |      |                       |         |
| No                   | 109 (61.6%)                     | 68 (38.4%)                   | 1                        | 0.21 | -                     | -       |
| Yes                  | 19 (50%)                        | 19 (50%)                     | 0.6 [0.3;1.3]           |      |                       |         |
| ADL                  |                                 |                               |                           |      |                       |         |
| Normal               | 92 (69.7%)                      | 40 (30.3%)                   | 1                        | <0.001* | 1                     | 0.010* |
| Abnormal             | 36 (43.9%)                      | 46 (56.1%)                   | 0.3 [0.2;0.6]           | 0.4 | [0.2 ; 0.8]          |         |
| IADL                 |                                 |                               |                           |      |                       |         |
| Normal               | 57 (73.1%)                      | 21 (26.9%)                   | 1                        | 0.002* | -                     | -       |
| Abnormal             | 71 (51.8%)                      | 66 (48.2%)                   | 0.4 [0.2; 0.7]          |      |                       |         |
| Cognitive impairment |                                 |                               |                           |      |                       |         |
| No                   | 78 (61.4%)                      | 49 (38.6%)                   | 1                        | 0.53 | -                     | -       |
| Yes                  | 48 (57.1%)                      | 36 (42.9%)                   | 0.8 [0.5;1.5]           |      |                       |         |
| BMI                  | 25.0 (±5.0)                     | 24.5 (±5.4)                  | 1.0 [0.9;1.1]           | 0.57 | -                     | -       |
| Falls                |                                 |                               |                           |      |                       |         |
| No                   | 86 (65.2%)                      | 46 (34.8%)                   | 1                        | 0.006* | -                     | -       |
| Yes                  | 24 (43.6%)                      | 31 (56.4%)                   | 0.4 [0.2;0.8]           |      |                       |         |
| Depression           |                                 |                               |                           |      |                       |         |
| No                   | 89 (66.9%)                      | 44 (33.1%)                   | 0.5 [0.3; 0.9]          | 0.020* | -                     | -       |
| Yes                  | 40 (50.0%)                      | 40 (50.0%)                   | 1                        |      |                       |         |
| ECOG-PS              |                                 |                               |                           |      |                       |         |
| < 2                  | 43 (66.2%)                      | 22 (33.8%)                   | 1                        | 0.010* | -                     | -       |
| ≥ 2                  | 10 (37.0%)                      | 17 (63.0%)                   | 0.3 [0.1;0.8]           |      |                       |         |
| Balducci’s Classification |                              |                               |                           |      |                       |         |
| I                    | 3 (60.0%)                       | 2 (40.0%)                    | 1                        | 0.58 | -                     | -       |
| II                   | 119 (60.4%)                     | 78 (39.6%)                   | 1.1 [0.2;6.2]           |      |                       |         |
| III                  | 7 (46.7%)                       | 8 (53.3%)                    | 0.6 [0.1;4.6]           |      |                       |         |
| Hearing deficit      |                                 |                               |                           |      |                       |         |
| No                   | 73 (65.2%)                      | 39 (34.8%)                   | 1                        | 0.11 | -                     | -       |
| Yes                  | 49 (53.8%)                      | 42 (46.2%)                   | 0.6 [0.4;1.1]           |      |                       |         |
| Visual deficit       |                                 |                               |                           |      |                       |         |
| No                   | 78 (62.9%)                      | 46 (37.1%)                   | 1                        | 0.38 | -                     | -       |
| Yes                  | 45 (56.3%)                      | 35 (43.7%)                   | 1.3 [0.7;2.3]           |      |                       |         |
| Numbers of frailty markers |                              |                               |                           |      |                       |         |
| Not-frail: 0 marker | 14 (93.3%)                      | 1 (6.7%)                     | 15.8 [1.9 ; 128.0]      | 21.8 | [2.8;172.8]           | 0.004* |
| (n = 15)             |                                 |                               |                           |      |                       |         |

(Continued)
is then a narrowing of the therapeutic window between meaningful, positive effects and unacceptable side effects. Our results suggest that frailty markers may be highly helpful in this situation.

Several prospective studies in oncology have demonstrated the predictive value of frailty markers for treatment toxicities. In two studies of older patients with colon cancer, patients with at least three markers had higher risks of developing postoperative major complications [19] and early death [39,40]. In a study of almost four hundred cancer patients, Makary et al. [18] showed that preoperative frailty was associated with an increased risk for postoperative complications. Patients with two or three markers had two times higher odds (95% CI, 1.18–3.60) of developing complications, and patients with four or five markers had 2.5 times higher odds (95% CI, 1.12–5.77), in contrast to the patients with one or no markers. The presence of at least three markers independently predicted an increase in length of stay (p < 0.001). Whatever the number of frailty markers, it appears that some markers have their own predictive value. Poor energy, abnormal nutrition and poor mobility were significantly predictive for early deaths [17,40,41]. Grip strength was also identified as an independent factor that predicted chemotoxicity [42] in older cancer patients and predicts adverse outcomes and postoperative morbi-mortality, regardless of age [43,44]. In a systematic review, Bohannon et al. concluded that grip strength is a predicting factor for mortality, disability, complications, and

| Table 2. (Continued) |
|----------------------|
| Univariate logistic regression | Multivariate logistic regression |
| Standard treatment with or without any changes | Modified treatment | Univariate OR [95%CI] | p | Multivariate OR [95%CI] | p-value |
| Pre frail: 1–2 markers (n = 110) | 79 (71.8%) | 31 (28.2%) | 3.2 [1.7 ; 6.1] | 4.0 [2;7;2] | <0.0001* |
| Frail: ≥ 3 markers (n = 92) | 36 (39.1%) | 56 (60.9%) | 1 | 0.0001* |
| Grip strength | | | | 1 | |
| Normal | 94 (69.7%) | 41 (30.4%) | 1 | < 0.0001* |
| Abnormal | 14 (28.6%) | 35 (71.4%) | 0.2 [0.1; 0.4] | |
| Physical activity | | | | | |
| Normal | 55 (80.9%) | 13 (19.1%) | 1 | < 0.0001* |
| Abnormal | 63 (48.8%) | 66 (51.2%) | 0.3 [0.1;0.5] | |
| Mobility | | | | | |
| Normal | 35 (77.8%) | 10 (22.2%) | 1 | 0.002* |
| Abnormal | 80 (51.6%) | 75 (48.4%) | 0.3 [0.1;0.7] | |
| Nutrition | | | | | |
| Normal | 58 (69.0%) | 26 (31.0%) | 1 | 0.030* |
| Abnormal | 71 (54.2%) | 60 (45.8%) | 0.5 [0.3;0.9] | |
| Energy | | | | | |
| Normal | 93 (62.0%) | 57 (38.0%) | 1 | 0.036* |
| Abnormal | 7 (36.8%) | 12 (63.2%) | 0.4 [0.1;0.9] | |

Abbreviations: CGA: Comprehensive Geriatric Assessment, OR: odds ratio, CI: Confidence Interval, ADL: Activities of Daily Living, IADL: Instrumental Activities of Daily Living, BMI: body mass index, ECOG–PS: Eastern Cooperative Oncology Group Scale of Performance Status
*: statistically significant

doi:10.1371/journal.pone.0149732.t002
increased length of stay in middle-aged and older patients [45]. Today, it’s too premature to recommend systematic assessment of frailty markers in older cancer patients. But, regarding these encouraging studies, further ones are warranted to define if the use of frailty markers is the proper instrument to assess the risks of mortality and treatment complications in both simple and more accurate way compared to CGA [46]. We can also hypothesized a combination of predictors including frailty markers, some domains of CGA and cancer characteristics will probably be more useful clinically in order to capture complexity of older cancer patients as suggested by Bergman H. and colleagues [47].

Our study presents several limitations. First, although realized in different hospitals, the geriatric assessment was performed by a single medical team. Therefore, the significant association observed in our study would have to be confirmed by similar studies conducted by other medical teams. Second, patients included in our study were referred by their specialists irrespectively of any screening tools; the geriatric status of patients not referred for CGA is unknown as other studies [48]. Our population is the one who really need to be assessed regarding the number of patient classified into groupe II or III of Balducci’s classification. Two important strengths of this study are the use of validated self-report and performance tests and the high median age of our sample (median age: 83 years).

Conclusion
In geriatric oncology, optimal management of older cancer patients is challenging, as the assessment of the underlying vulnerability guides decision-making. Results of our study suggest that the use of frailty markers could help oncologists and geriatricians in their decision-making. Longitudinal studies are warranted to better determine their use in geriatric oncology.

Acknowledgments
The authors would like to thank all Ms Aïda Langar for her editorial assistance, Mr Quentin Alitta, chef de projet institut Silvermed, who edited the manuscript, all patients and their treating physicians.

Author Contributions
Conceived and designed the experiments: AF LD F. Rousseau F. Retornaz. Performed the experiments: AF F. Retornaz. Analyzed the data: AF VP HB F. Rousseau CM F. Retornaz. Contributed reagents/materials/analysis tools: AF F. Retornaz. Wrote the paper: AF LD VP HB F. Rousseau CM F. Retornaz.

References
1. Pal SK, Katheria V, Hurria A (2010) Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 60:120–32. doi:10.3322/caac.20059 PMID: 20173172
2. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Litchman S et al. (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241–52. PMID: 16084735
3. Bernabei R, Venturiero V, Tarsitani P, Gambassi G (2000) The comprehensive geriatric assessment: when, where, how. Crit Rev Oncol Hematol 33:45–56. PMID: 10714961
4. Chen CC-H, Kenefick AL, Tang ST, McCorkile R (2004) Utilization of comprehensive geriatric assessment in cancer patients. Crit. Rev. Oncol Hematol. 49:53–67. PMID: 14734155
5. Liu JJ, Extermann M (2012) Comprehensive geriatric assessment and its clinical impact in oncology. Clin Geriatr Med 28:19–31. doi: 10.1016/j.cger.2011.10.001 PMID: 22326033
6. Repetto L, Venturino A, Fratino, Serraino D, Troisi G, Gianni W et al. (2003) Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 39:870–80. PMID: 12706355
7. Puts MT, Hardt J, Monette J, Girir V, Springall E, Alibhai SM (2012) Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst 104:1133–63. doi: 10.1093/jnci/djs285 PMID: 2285269

8. Ferrucci L, Guralnik JM, Cavazzini C, Bandinelli S, Lauterati F, Bartali B et al. (2003) The frailty syndrome: a critical issue in geriatric oncology. Crit. Rev. Oncol Hematol 46:127–37. PMID: 12711358

9. Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machtei Eymenga AN (2007) Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43:2161–9. PMID: 17855074

10. Aparicio T, Girard L, Bouarioua N, Patry C, Legrain S, Soule JC (2011) A mini geriatric assessment helps treatment decision in elderly patients with digestive cancer. A pilot study. Crit Rev Oncol Hematol 77:63–9. doi: 10.1016/j.critrevonc.2010.01.003 PMID: 20116276

11. Chaib P, Magné N, Breton S, Watson S, Duron JJ, Hannoun L et al. (2011) Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol. 79:302–7. doi: 10.1016/j.critrevonc.2010.08.004 PMID: 20888781

12. Girre V, Falcou MC, Gisselbrecht M, Gridel G, Mosseri V, Bouleuc C et al. (2008) Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci 63:724–30. PMID: 18693227

13. Barthelemy P, Heitz D, Mathelin C, Polesi H, Asmane I; Litique V et al. (2011) Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals. Crit Rev Oncol Hematol 79:196–204. doi: 10.1016/j.critrevonc.2010.06.005 PMID: 20655243

14. Caillet P, Canoui-Poitrine F, Vouriot J, Berie M, Reinald N, Krypciak S et al. (2011) Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 29:3636–42. doi: 10.1200/JCO.2010.31.0664 PMID: 21709194

15. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al. (2001) Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol Sci Med Sci 56:M146–56. PMID: 11253156

16. Bande-Remoche K, Xue Q-L, Ferrucci L, Walston J, Guralnik JM, Chaves P et al. (2006) Phenotype of frailty: characterization in the women’s health and aging studies. J. Gerontol. A Biol Sci Med 61:262–66.

17. Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C et al. (2012) Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. J Clin Oncol 30:1829–34. doi: 10.1200/JCO.2011.35.7442 PMID: 22508806

18. Mackary MA, Segev DL, Pronovost PJ, Syin D, Bandeen-Roche K, Patel P et al. (2010) Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 210:901–8. doi: 10.1016/j.jamcollsurg.2010.01.028 PMID: 20510798

19. Tan KY, Kawamura YJ, Tokomitsu A, Tang T (2012) Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized. Am J Surg 204:139–43. doi: 10.1016/j.amjsurg.2011.08.012 PMID: 22178483

20. Retomaz F, Monette J, Batist G, Monette M, Sourial N, Small D et al. (2008) Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. J. Gerontol. A Biol Sci Med Sci 63:518–22. PMID: 18511757

21. Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649.

22. Katz S (1983) Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 31:721–7. PMID: 6418786

23. Fillenbaum GG, Smyer MA (1981) The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36:428–34. PMID: 7250274

24. Retomaz F, Saux YM, Ibrahimi JL, Monette J, Bergman H et al. (2007) Comparison of the frailty syndrome: a critical issue in geriatric oncology. Crit. Rev. Oncol Hematol 46:127–37. PMID: 12711358

25. Falandry C, Weber B, Savoye AM, Tinquaut F, Tredan O, Sevin E et al. (2013) Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol 24:2808–13. doi: 10.1093/annonc/mdt360 PMID: 24061628

26. Folstein MF, Folstein SE, McHugh PR (1975) “Mini Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–98. PMID: 1202204

27. Borson S, Scanlan JM, Watanabe J, Tu SP, Lessig M (2005) Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State examination in a multiethnic sample. J Am Geriatric Soc 53:871–4.
28. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695–9. PMID: 15817019
29. Cahn DA, Salmon DP, Monsch AU, Butters N, Wiederholt WC, Corey-Bloom J et al. (1996) Screening for dementia of the Alzheimer type in the community: the utility of the Clock Drawing Test. Arch Clin Neuropsychol 11:529–39. PMID: 15488458
30. Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontology: A Guide to Assessment and Intervention. The Haworth Press 165–73.
31. Cook Z, Kirk S, Lawrenson S, Sandford S (2005) Use of BMI in the assessment of undernutrition in older subjects: reflecting on practice. Proc Nutr Soc 64:313–7. PMID: 16048662
32. Balducci L (2007) Aging, Frailty, and Chemotherapy. Cancer Control 14: 7–12 PMID: 17242666
33. Cornali C, Franzoni S, Frisoni GB, Trabucchi M (2005) Anorexia as an independent predictor of mortality. J Am Geriatr Soc 53:354–5. PMID: 15673368
34. Davis HS, MacPherson K, Merry HR, Wentzel C, Rockwood K (2001) Reliability and validity of questions about exercise in the Canadian Study of Health and Aging. Int Psychogeriatr 13 Supp 1:177–82.
35. Puts MTE, Monette J, Girre V, Pepe C, Monette M, Assouline S et al. (2011) Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78:138–49. doi: 10.1016/j.critrevonc.2010.04.003 PMID: 20444620
36. Guo CB, Zhang W, Ma DQ, Zhang KH Huang JQ (1996) Hand grip strength: an indicator of nutritional state and the mix of postoperative complications in patients with oral and maxillofacial cancers. Br J Oral Maxillofac Surg 34:325–7. PMID: 8866070
37. Kalfarentzos F, Spiriotis J, Velimezis G, Dougenis D, Androulakis J (1989) Comparison of forearm muscle dynamometry with nutritional prognostic index, as a preoperative indicator in cancer patients. JPEN J Parenter Enteral Nutr 13:34–6. PMID: 2926977
38. Bohannon RW (2008) Hand-grip dynamometry predicts future outcomes in aging adults. J Geriatr Phys Ther 31:3–10. PMID: 18498802
39. Balducci L (2013) Frailty: a common pathway in aging and cancer. Interdiscip Top Gerontol 38:61–72. doi: 10.1159/000343586 PMID: 23503516
40. Sourial N, Bergman H, Karunanathan S, Wolfson C, Payette H, Gutierrez-Robledo LM et al. (2013) Implementing frailty into clinical practice: a cautionary tale. J Gerontol A Biol Sci Med Sci 68: 1505–11. doi: 10.1093/gerona/glt053 PMID: 23640761
41. Rouge-Bugat ME, Gerard S, Bialiardy L, Beyne-Rauzy O, Boussier N, Perrin A et al. (2013) Impact of an oncogeriatric consulting team on therapeutic decision making. J Nutr Health Aging 17:473–8. doi: 10.1007/s12603-012-0435-z PMID: 23636550